Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest

Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest

Abstract Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a major clinical challenge. Methods Th...

Full description

Bibliographic Details
Main Authors: Jian Zhou, Meijia Chang, Jing Li, Tao Fang, Jie Hu, Chunxue Bai
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Respiratory Research
Subjects:
Non-small cell lung cancer
Annexin A5
Gefitinib
Polo-like kinase 1
Online Access:http://link.springer.com/article/10.1186/s12931-018-0804-1

Similar Items

Similar Items